The IRE1 and PERK arms of the unfolded protein response promote survival of rhabdomyosarcoma cells.


Journal

Cancer letters
ISSN: 1872-7980
Titre abrégé: Cancer Lett
Pays: Ireland
ID NLM: 7600053

Informations de publication

Date de publication:
10 10 2020
Historique:
received: 15 04 2020
revised: 25 06 2020
accepted: 08 07 2020
pubmed: 18 7 2020
medline: 20 1 2021
entrez: 18 7 2020
Statut: ppublish

Résumé

Rhabdomyosarcoma (RMS), the most common soft-tissue sarcoma, is associated with a low 5-year survival and harsh treatment side effects, underscoring an urgent need for therapy. The unfolded protein response (UPR) is activated in response to endoplasmic reticulum (ER) stress, where three ER stress receptors, IRE1, PERK and ATF6, aim to restore cellular homeostasis. The UPR is pro-tumourigenic in many cancers. In this study, we investigate basal UPR activity in RMS. Basal activation of IRE1 and PERK was observed in RMS cell lines, which was diminished upon addition of the IRE1 RNase inhibitor, MKC8866, or PERK inhibitor, AMGEN44. UPR inhibition caused a reduction in cell viability, cell proliferation and inhibition of long-term colony formation in both subtypes of RMS. Alveolar RMS (ARMS) subtype was highly sensitive to IRE1 inhibition, whereas embryonal RMS (ERMS) subtypes responded more markedly to PERK inhibition. Further investigation revealed a robust activation of senescence upon UPR inhibition. For the first time, the UPR is implicated in RMS biology and phenotype, and inhibition of UPR signalling reduces cell growth, suggesting that the UPR may be a promising target in RMS.

Identifiants

pubmed: 32679165
pii: S0304-3835(20)30364-5
doi: 10.1016/j.canlet.2020.07.009
pii:
doi:

Substances chimiques

EIF2AK3 protein, human EC 2.7.11.1
ERN1 protein, human EC 2.7.11.1
Protein Serine-Threonine Kinases EC 2.7.11.1
eIF-2 Kinase EC 2.7.11.1
Endoribonucleases EC 3.1.-

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

76-88

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Auteurs

Nicole McCarthy (N)

Institute for Experimental Cancer Research in Pediatrics, Goethe-University Frankfurt, Komturstr. 3a, 60528, Frankfurt, Germany.

Nadezda Dolgikh (N)

Institute for Experimental Cancer Research in Pediatrics, Goethe-University Frankfurt, Komturstr. 3a, 60528, Frankfurt, Germany.

Susan Logue (S)

Rady Faculty of Health Sciences, University of Manitoba, Canada.

John B Patterson (JB)

Orinove Inc., Newbury Park, CA, USA.

Qinping Zeng (Q)

Fosun Orinove PharmaTech Inc., Suzhou, Jiangsu, China.

Adrienne M Gorman (AM)

Apoptosis Research Centre, National University of Ireland Galway, Galway, Ireland; School of Natural Sciences, National University of Ireland Galway, Galway, Ireland.

Afshin Samali (A)

Apoptosis Research Centre, National University of Ireland Galway, Galway, Ireland; School of Natural Sciences, National University of Ireland Galway, Galway, Ireland.

Simone Fulda (S)

Institute for Experimental Cancer Research in Pediatrics, Goethe-University Frankfurt, Komturstr. 3a, 60528, Frankfurt, Germany; German Cancer Consortium (DKTK), Partner Site Frankfurt, Germany; German Cancer Research Center (DKFZ), Heidelberg, Germany. Electronic address: simone.fulda@kgu.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH